基于微小残留病灶的终点用于多发性骨髓瘤临床试验加速评估:多项随机试验个体患者数据的汇总分析
该汇总分析纳入20项随机多中心试验的个体患者数据,其中11项研究(4773例患者)数据充分被分析,评估治疗开始后9或12个月以10^-5阈值判定的MRD-CR能否作为PFS和OS的中间终点。结果显示9和12个月MRD-CR在初诊移植合格、初诊移植不合格及复发难治患者中均与PFS强相关,全局OR为3.06至16.24,95%CI均不包含1.0,OS结果类似。
要点
- 9或12个月时以10^-5阈值判定的MRD-CR与初诊移植合格、初诊移植不合格及复发难治患者的PFS强相关。
- 全局OR范围为3.06至16.24,所有95%CI均不包含1.0。
- 试验层面相关性R²为0.61至0.70,初诊人群中更强(R²为0.67至0.78),OS结果类似。
核心结论
- 研究结果支持将治疗开始后9或12个月时以10^-5阈值判定的MRD-CR作为中间终点,用于未来初诊移植合格、初诊移植不合格及复发难治多发性骨髓瘤试验的加速审批。
研究设计与样本
- 汇总分析收集了20项随机多中心试验的个体患者数据。
- 其中11项研究(4773例患者)数据充分被分析,评估9或12个月时以10^-5阈值判定的MRD-CR能否合理预测新药对PFS和OS的临床获益。
- 全局比值比(OR)采用双变量Plackett Copula模型估计。
- 支持性评估包括通过线性回归(R²加权最小二乘)和Copula(R²Copula)模型评估MRD-CR终点与PFS/OS的治疗效应相关性。
主要发现
- 在初诊移植合格、初诊移植不合格及复发难治患者中,9和12个月MRD-CR均在患者层面与PFS强相关,全局OR范围为3.06至16.24,所有95%CI均不包含1.0。
- 汇总三个人群后观察到鼓励性的试验层面相关性(R²为0.61至0.70),初诊人群中更强(R²为0.67至0.78)。
- OS观察到类似结果。
关键数值与推荐
- MRD-CR以10^-5为阈值判定。
- 评估时间点为治疗开始后9或12个月。
- 全局OR范围为3.06至16.24,所有95%CI均不包含1.0。
- 试验层面相关性R²为0.61至0.70(汇总三个人群),初诊人群为0.67至0.78。
临床怎么用
- 作者认为研究结果支持将治疗开始后9或12个月时以10^-5阈值判定的MRD-CR作为中间终点,用于未来初诊移植合格、初诊移植不合格及复发难治多发性骨髓瘤试验的加速审批。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Newly approved drugs and combinations treating multiple myeloma (MM) have resulted in substantial improvements in patients' survival. To deliver rapid access to newer therapies, an earlier end point to expedite clinical trials is needed. Our objective was to evaluate the minimal residual disease-negative complete response (MRD-CR) as an intermediate end point for progression-free survival (PFS) and overall survival (OS) in newly diagnosed (ND) transplant-eligible (NDTE) patients, ND transplant-ineligible (NDTinE) patients, and patients with relapsed/refractory (RR) MM. PATIENTS AND METHODS: Individual patient data from 20 randomized multicenter trials were collected. Eleven studies (4,773 patients) with sufficient data were analyzed to evaluate whether 9- or 12-month MRD-CR classified at a 10-5 threshold could be reasonably likely to predict the clinical benefit of new agents regarding PFS and OS. Global odds ratio (OR) was estimated using the bivariate Plackett Copula model. Supportive evaluation included correlations of the treatment effects on MRD-CR end points and PFS/OS, evaluated by both linear regression (R2weighted least squared) and Copula (R2Copula) models. RESULTS: The analysis demonstrated that both 9- and 12-month MRD-CR strongly correlated with PFS at patient level in NDTE patients, NDTinE patients, and patients with RRMM. Global ORs ranged from 3.06 to 16.24, all with 95% CIs excluding 1.0. Encouraging trial-level correlations (R2, 0.61-0.70) were observed by pooling three populations and were stronger (R2, 0.67-0.78) in the ND population. Similar results were observed for OS. CONCLUSION: Our findings provided the support for use of MRD-CR classified at a 10-5 threshold at either 9 or 12 months after starting of the treatment, as an intermediate end point to support accelerated approvals, in future trials in NDTE patients, NDTinE patients, and patients with RRMM.
引用
- Shi Q, Paiva B, Pederson LD, et al. Minimal Residual Disease-Based End Point for Accelerated Assessment of Clinical Trials in Multiple Myeloma: A Pooled Analysis of Individual Patient Data From Multiple Randomized Trials. J Clin Oncol. 2025. PMID: 39938021. doi:10.1200/JCO-24-02020
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。